ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Gender- and sex-dependent variations in heart failure and cardiomyopathies: a review of the literature.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a clinical syndrome that can present as an acute or chronic condition resulting from various cardiovascular (CV) diseases. It poses a significant global health burden and affects individuals regardless of biological sex. HF can be caused by various differing etiologies exhibiting different rates of disease progression and mortality. Treatment of HF is often approached using a one-size-fits-all strategy that overlooks sex and gender differences, relying solely on left ventricular ejection fraction as the clinical parameter. This is due to a lack of evidence and subsequent missing deepened understanding of nuances of disease manifestation, course, and outcome. Biological sex (defined as biological aspects of having female or male body) and gender (society norms and roles of women and men) are known to substantially influence prognosis, age of disease onset, as well as severity in CV disease and subsequent HF. However, varying quality and availability of supporting evidence and subsequently unmet diagnostic and therapeutic needs exist for general HF and cardiomyopathy (CM) management. This review aims to elucidate the influence of sex and gender on the development and treatment of HF and CM as a basis for advancing personalized diagnosis and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.